geoscience.net logo
+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma


, : A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma. Respiratory Medicine 104(8): 1121-1130

To compare the efficacy of ciclesonide (80 microg/day) with fluticasone propionate (200 microg/day) in mild to moderate persistent asthma. Patients aged 12-75 years and previously treated with low doses of inhaled corticosteroid (fluticasone propionate 250 microg/day or equivalent) entered a 2-4 week run-in period during which only rescue medication was permitted. For inclusion into the double-blind, 24-week treatment period, patients had to show a forced expiratory volume in 1s (FEV(1)) of 61-90% predicted and a decrease in FEV(1) during run-in of >or=10%. Patients (n = 480) were randomized to ciclesonide 80 microg (ex-actuator) once daily in the evening or fluticasone propionate 100 microg (ex-valve) twice daily. The primary efficacy variable was the change from baseline in FEV(1). Secondary efficacy variables included asthma control and asthma-specific quality of life. Both treatments significantly increased FEV(1) and other lung function variables from baseline (p < 0.0001, both groups, all variables). The least squares mean increases in FEV(1) were 0.46L (ciclesonide) and 0.52L (fluticasone propionate); non-inferiority of ciclesonide to fluticasone propionate was demonstrated (p = 0.0002, per-protocol analysis). Five patients in each group experienced asthma exacerbations. Improvements in the percent of days with asthma control (days with no asthma symptoms and no use of rescue medication) and asthma-specific quality of life were comparable between treatments. The study confirmed similar efficacy of ciclesonide 80 microg once daily and fluticasone propionate 100 microg twice daily in mild to moderate persistent asthma. The low dose of ciclesonide was efficacious during long-term treatment. EudraCT number: 2004-001072-39.

US$19.90

PMID: 20430601

DOI: 10.1016/j.rmed.2010.03.032


Other references

Williams, L.M.; Morrow, B.; Lansky, A.; Beck, L.F.; Barfield, W.; Helms, K.; Lipscomb, L.; Whitehead, N., 2003: Surveillance for selected maternal behaviors and experiences before, during, and after pregnancy. Pregnancy Risk Assessment Monitoring System (PRAMS), 2000. Various maternal behaviors and experiences are associated with adverse health outcomes for both the mother and the infant. These behaviors and experiences can occur before pregnancy (e.g., insufficient intake of folic acid), during pregnancy (e.g....

Srinivasan, H.; Rao, K.S.; Iyer, C.G., 1982: Discrepancy in the histopathological features of leprosy lesions in the skin and peripheral nerve. Report of a preliminary study. Simultaneous biopsies of the skin and a cutaneous nerve were done in 36 randomly selected leprosy patients and the histopathological features of the lesion in the two tissues were compared. A discrepancy was noticed in 21 instances. In 19 of these...

Högberg, U.; Wall, S.; Wiklund, D.E., 1990: Risk determinants of perinatal mortality in a Swedish county, 1980-1984. A retrospective case-referent study was performed to analyse risk factors of perinatal mortality. Overweight defined by body mass index, smoking greater than 10 cigs/day, infertility, earlier birth weight, earlier perinatal death were significant...

D.N.nzio, C.; Presicce, F.; Pirozzi, L.; Castellan, P.; Schips, L.; Cindolo, L.; Lombardo, R.; Tubaro, A., 2016: The Current Indications and the Benefits of Combining a β3-Agonist with an Anticholinergic for the Treatment of OAB. Combination therapy with anti-muscarinics (AMs) and β3 agonists (β3As) has recently been proposed as a possible treatment for the management of patients with Overactive Bladder (OAB). A National Center for Biotechnology Information PubMed search...

Woods, M.J.; Prasad, M.; Maher, M.J., 1972: Effect of steaming on yield and nutrient content of tomatoes grown in three substrates and on physical properties of the substrate. Steam sterilization before each crop increased the yield of tomatoes grown on sphagnum peat for 3 years. The increase became more pronounced with time, and the effect of steaming was greater in the summer crop, which had a duration of 6 months, th...

Taher Shamsi A.; Ardeshir A., 2000: Tehran Aquifer environmental problems, a case study. Pages 513-514 2000

D.B.cquer, D.; D.B.cker, G.; Kornitzer, M., 2000: Prevalences of ECG findings in large population based samples of men and women. Objective: To obtain accurate estimates of the prevalence of ECG abnormalities in the general population and to describe them in relation to age, sex, and some lifestyle related factors. Design: The results were obtained from the records of 47 358...

Kawase, M.; Miyamae, H.; Kurihara, T., 1998: A general method for the preparation of 5-trifluoromethylated oxazoles from alpha-amino acids. The reactions of N-acyl-N-benzyl-alpha-amino acids (1) or N-acylprolines (5) with trifluoroacetic anhydride in the presence of pyridine afford 5-trifluoromethyloxazoles (2 or 7) in good yields. The reaction could proceed through the transient form...

Bedwell, R.M.; Spielvogel, H.; Bellido, D.; Vitzthum, V.J., 2017: Factors Influencing the Use of Biomedical Health Care by Rural Bolivian Anemic Women: Structural Barriers, Reproductive Status, Gender Roles, and Concepts of Anemia. Non-pregnant women from a rural town and its surrounding region were tested for anemia. During phase 1 (n = 181), anemic women received a written recommendation for low-cost purchase of iron pills at the nearest health center. They were subsequent...

Shibasaki, M.; Fujimori, A.; Kusayama, T.; Tokioka, T.; Satoh, Y.; Okazaki, T.; Uchida, W.; Inagaki, O.; Yanagisawa, I., 1997: Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs. The antihypertensive activity of YM358, 2,7-diethyl-5-[[2'-(1 H-tetrazol-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]tri azole potassium salt monohydrate, a new nonpeptide angiotensin II receptor antagonist, was characterized in rats...